# A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

> **NCT00401765** · PHASE1 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** CNTO 328
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00401765
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401765, "A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00401765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*